Abstract
Introduction. To assess the impact of intravesically injected botulinum A toxin (BoNT/A) upon bladder pain, urological complaints, symptoms of anxiety and depression, and Quality of Life (QoL) in patients with painful bladder symptoms (PBS) refractory to conventional treatment. Patients and Methods. In this prospective study 14 patients received one injection of BoNT/A (200 U diluted in 20 ml 0.9% NaCl), under cystoscopic guidance. At pre- and 3 months post- treatment all patients underwent an urological assessment (voiding diary, urodynamics), a pain quantification on a visual analog scale (VAS), an evaluation with the 14-item Hamilton Anxiety Rating Scale (HAM-A) to assess symptoms of psychic and somatic anxiety, an evaluation with the Hamilton Depression Rating Scale (HAM-D) to assess depression, and the 36-item Medical Outcomes Study Short Form (SF-36) to assess QoL. Results. At pre-treatment all 14 patients had increased daytime and nighttime urinary frequency and high VAS scores. Nine patients had pathological HAM-A scores and all had pathological HAM-D scores. At the 3-month follow-up 10/14 patients reported a subjective improvement in pain. Mean VAS score, mean daytime and nighttime urinary frequency decreased significantly (p < 0.01, < 0.01 and < 0.01, respectively). All domains in SF-36 and HAM-A significantly improved (p < 0.01). All domains, except weight and sleep disorders, significantly improved in HAM-D, particularly somatoform symptoms (p < 0.01), cognitive performance (p < 0.01), and circadian variations (p < 0.01). Conclusion. In patients with refractory PBS with symptoms of anxiety, depression and poor QoL, BoNT/A intravesical treatment reduced bladder pain, improved psychological functioning, and well-being.
Keywords: Botulinum A toxin, painful bladder syndrome, depression, anxiety
Current Drug Delivery
Title: Botulinum A Toxin Intravesical Injections for Painful Bladder Syndrome: Impact Upon Pain, Psychological Functioning and Quality of Life
Volume: 7 Issue: 5
Author(s): Antonella Giannantoni, Roberta Cagini, Michele Del Zingaro, Silvia Proietti, Roberto Quartesan, Massimo Porena and Massimiliano Piselli
Affiliation:
Keywords: Botulinum A toxin, painful bladder syndrome, depression, anxiety
Abstract: Introduction. To assess the impact of intravesically injected botulinum A toxin (BoNT/A) upon bladder pain, urological complaints, symptoms of anxiety and depression, and Quality of Life (QoL) in patients with painful bladder symptoms (PBS) refractory to conventional treatment. Patients and Methods. In this prospective study 14 patients received one injection of BoNT/A (200 U diluted in 20 ml 0.9% NaCl), under cystoscopic guidance. At pre- and 3 months post- treatment all patients underwent an urological assessment (voiding diary, urodynamics), a pain quantification on a visual analog scale (VAS), an evaluation with the 14-item Hamilton Anxiety Rating Scale (HAM-A) to assess symptoms of psychic and somatic anxiety, an evaluation with the Hamilton Depression Rating Scale (HAM-D) to assess depression, and the 36-item Medical Outcomes Study Short Form (SF-36) to assess QoL. Results. At pre-treatment all 14 patients had increased daytime and nighttime urinary frequency and high VAS scores. Nine patients had pathological HAM-A scores and all had pathological HAM-D scores. At the 3-month follow-up 10/14 patients reported a subjective improvement in pain. Mean VAS score, mean daytime and nighttime urinary frequency decreased significantly (p < 0.01, < 0.01 and < 0.01, respectively). All domains in SF-36 and HAM-A significantly improved (p < 0.01). All domains, except weight and sleep disorders, significantly improved in HAM-D, particularly somatoform symptoms (p < 0.01), cognitive performance (p < 0.01), and circadian variations (p < 0.01). Conclusion. In patients with refractory PBS with symptoms of anxiety, depression and poor QoL, BoNT/A intravesical treatment reduced bladder pain, improved psychological functioning, and well-being.
Export Options
About this article
Cite this article as:
Giannantoni Antonella, Cagini Roberta, Del Zingaro Michele, Proietti Silvia, Quartesan Roberto, Porena Massimo and Piselli Massimiliano, Botulinum A Toxin Intravesical Injections for Painful Bladder Syndrome: Impact Upon Pain, Psychological Functioning and Quality of Life, Current Drug Delivery 2010; 7 (5) . https://dx.doi.org/10.2174/156720110793566317
DOI https://dx.doi.org/10.2174/156720110793566317 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Alzheimer Research Recent Patents on Perovskite Ferroelectric Nanostructures
Recent Patents on Nanotechnology The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neurocognitive and Psychiatric Markers for Addiction: Common vs. Specific Endophenotypes for Heroin and Amphetamine Dependence
Current Topics in Medicinal Chemistry Safety and Efficacy of Melatonin in Pediatric Migraine Prophylaxis
Current Drug Safety <i>Piper sarmentosum</i> Roxb. Attenuates Beta Amyloid (Aβ)-Induced Neurotoxicity <i>Via</i> the Inhibition of Amyloidogenesis and Tau Hyperphosphorylation in SH-SY5Y Cells
Current Alzheimer Research The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research The Applications of Clustering Methods in Predicting Protein Functions
Current Proteomics Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Lifestyle Changes among ACS Survivors in Arabian Gulf Countries (Gulf COAST Registry)
Current Vascular Pharmacology Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Current Medicinal Chemistry Prospects for the Resistance to HIV Protease Inhibitors: Current Drug Design Approaches and Perspectives
Current Pharmaceutical Design Quantitative Investigation of Biomolecular Interactions in Crowded Media by Fluorescence Spectroscopy, a Good Choice
Current Protein & Peptide Science The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Objective Biological Measures for the Assessment and Management of Auditory Processing Disorder
Current Pediatric Reviews TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology